Cargando…

Resistance to PARP-Inhibitors in Cancer Therapy

The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers. Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montoni, Alicia, Robu, Mihaela, Pouliot, Émilie, Shah, Girish M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583007/ https://www.ncbi.nlm.nih.gov/pubmed/23450678 http://dx.doi.org/10.3389/fphar.2013.00018

Ejemplares similares

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Characterization of the interactions of PARP-1 with UV-damaged DNA in vivo and in vitro
por: Purohit, Nupur K., et al.
Publicado: (2016)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

Identification of PARP12 Inhibitors By Virtual Screening and Molecular Dynamics Simulations
por: Almeleebia, Tahani M., et al.
Publicado: (2022)

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
por: Wang, Chuanlin, et al.
Publicado: (2022)

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more
por: Wang, Zhi-Bin, et al.
Publicado: (2023)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
por: Tian, Xiaojiang, et al.
Publicado: (2022)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
por: Bisht, Priya, et al.
Publicado: (2022)

A multi-task FP-GNN framework enables accurate prediction of selective PARP inhibitors
por: Ai, Daiqiao, et al.
Publicado: (2022)

Methods to Study Intracellular Movement and Localization of the Nucleotide Excision Repair Proteins at the DNA Lesions in Mammalian Cells
por: Robu, Mihaela, et al.
Publicado: (2020)

Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement
por: Yu, Ling, et al.
Publicado: (2023)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
por: Abu-Sanad, Atlal, et al.
Publicado: (2015)

Research Progress on PARP14 as a Drug Target
por: Qin, Wei, et al.
Publicado: (2019)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges
por: Zhang, Xi, et al.
Publicado: (2022)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Role of Akt Activation in PARP Inhibitor Resistance in Cancer
por: Gallyas, Ferenc, et al.
Publicado: (2020)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Advances in the use of PARP inhibitor therapy for breast cancer
por: McCann, Kelly E, et al.
Publicado: (2018)

The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
por: Hunia, Jaromir, et al.
Publicado: (2022)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment
por: Jackson, Lindsey M, et al.
Publicado: (2022)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
por: Zhao, Quanfeng, et al.
Publicado: (2022)

Human PARP1 substrates and regulators of its catalytic activity: An updated overview
por: Zhu, Tao, et al.
Publicado: (2023)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eoqch9tgg1kahgegurdt4e3ruh